Editorial review · United States
BPC-157
Source review:
Approval and product status
Still being studied; no FDA-approved BPC-157 product identified
A peptide sequence, a nominated bulk substance, a clinical-study product, and a consumer vial are separate evidence objects. Identity and product quality cannot be assumed from the name.
This is the status described in the dated review. It is not a live FDA database check.
What was measured in people?
- Health outcomes · Limited
- Small uncontrolled pilots cannot establish a patient benefit.
- Body effects · Limited
- Human exposure and pharmacokinetic characterization remain sparse.
A change in a hormone or body signal does not by itself prove a health benefit.
Limits that matter
Not independently medically reviewed. This tool does not recommend treatment.
The site will not provide self-injection, reconstitution, dosing, sourcing, or stack instructions. “Research use only” does not establish quality or make a product appropriate for human use.
Still unknown: The available evidence still does not establish that BPC-157 safely heals sports injuries or other conditions in people. Early, uncontrolled, or registered research is not the same as a replicated patient benefit, and a trial listing is not a positive result.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Exact product records in this review
These are selected records, not every product or form. A route means how a product enters the body.
No product label record is included here. That is not a separate approval decision. Read the status and sources above.
What the research shows
The preclinical literature contains positive signals in cell and animal models, including tendon-healing models. Small human pilot work and registered clinical research now exist, but do not establish a clinical effect in people. FDA's July 2026 PCAC briefing evaluated BPC-157-related bulk substances for a nominated ulcerative-colitis use and documented evidence and safety gaps. That advisory-stage record supports scrutiny; it is not a final FDA determination.
Read all BPC-157 claims and their limitsSources used in the full review
A source is not support for every claim. Use the claim links above or the full review to check what each source supports.
- July 2026 PCAC briefing on BPC-157-related bulk drug substances
U.S. Food and Drug Administration · FDA review · 2026
Source accessed
- Certain bulk drug substances for use in compounding that may present significant safety risks
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- BPC-157 as an investigational peptide therapeutic: translational development barriers
PubMed · Pharmaceutics · Science review · 2026
Source accessed
- Safety of intravenous infusion of BPC157 in humans: a pilot study
PubMed · Alternative Therapies in Health and Medicine · Human pilot · 2025
Source accessed
- Promoting effect of BPC 157 on tendon healing: tendon outgrowth, cell survival, and migration
PubMed · Journal of Applied Physiology · Preclinical · 2011
Source accessed
- 2026 prohibited list
World Anti-Doping Agency · Anti-doping · 2026
Source accessed
- BPC 157 for acute hamstring muscle strain repair
ClinicalTrials.gov · Trial registry · 2026
Source accessed